[{"id":"9cc869bf-a060-4c14-b8ae-e3e71379c41c","acronym":"NK-REALM","url":"https://clinicaltrials.gov/study/NCT04395092","created_at":"2021-01-18T21:12:39.215Z","updated_at":"2024-07-02T16:36:28.786Z","phase":"Phase 2","brief_title":"Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)","source_id_and_acronym":"NCT04395092 - NK-REALM","lead_sponsor":"Kiadis Pharma","biomarkers":" FLT3 • HLA-DRB1","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • K-NK002"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/13/2020","start_date":" 11/13/2020","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2021-06-22"}]